Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C

Fig. 4

Exogenous expression of p65 abrogated the effect of curcumin on MUC1-C expression and cell growth inhibition. a-b PC3 and DU145 cells were transfected with the control (pCMV6) or expression constructs of p65 for 24 h before exposing the cells to curcumin for an additional 24 h. Afterwards, p65 and MUC1-C protein expression were determined by Western blot. c-d PC3 and DU145 cells were transfected with the control (pCMV6) or expression construct of p65 for 24 h before exposing the cells to curcumin for an additional 48 h. Afterwards, the cell viability was determined using the MTT assay as described in the Materials and Methods section and was expressed as percentage of control in the mean ± SD of three separate experiments. Insert on the upper panel represented the protein levels of p65 as determined using Western blot. β-actin was used as internal control. Values in bar graphs were given as the mean ± SD from three independent experiments performed in triplicate. *Indicates significant difference as compared to the untreated control group (P < 0.05). **Indicates significant difference from curcumin treated alone (P < 0.01)

Back to article page